7th In-House Impact: Life Sciences Summit

7th In-House Impact: Life Sciences Summit advances strategic life sciences leadership by examining regulatory change, AI governance, compliance maturity, intellectual property protection, deal readiness, and cross-border operational resilience to strengthen enterprise value and decision-making under market and policy uncertainty.

Key Topics

• Regulatory volatility and FDA signal interpretation for executive decision-making
• AI governance frameworks for safe and scalable adoption in life sciences
• Compliance maturity and enforcement risk reduction strategies
• Pricing strategy and valuation protection under market and policy shifts
• IPO readiness and acquisition risk mitigation for enterprise stability
• Deal strategy and merger alignment for valuation confidence and board certainty
• Responsible AI deployment for legal oversight and operational efficiency
• AI-assisted regulatory submissions and FDA documentation acceleration
• Intellectual property and trade secret protection for competitive positioning
• Cross-functional governance and enterprise alignment for value preservation
• Geopolitical and cross-border risk management for operational continuity
• Board engagement and leadership development for strategic resilience

Who should Attend

• Life sciences executives and senior leadership teams
• General counsels and legal department leaders
• Regulatory affairs and compliance professionals
• Biotech and pharmaceutical strategy leaders
• Corporate development and M&A specialists
• Intellectual property and risk management professionals
• AI governance and digital transformation leaders